U.S. ResidentsRecurrence Post Adjuvant Therapy
| 69 years old 23 months since diagnosis |
Gastric KIT+ GIST Original tumor: 8 cm Mitotic rate: ≤5/50 HPFs |
Patients who end adjuvant therapy and subsequently experience recurrence now have advanced disease. They need to know:
- GLIVEC is the only therapy approved for first-line use in the advanced setting1,2
- Restart GLIVEC therapy until disease progression or intolerance1,3
- In a clinical trial, GLIVEC provided nearly 6 times the overall survival in advanced KIT+ GIST (57 months with GLIVEC vs 10 months before the GLIVEC era)4,5
- Surgical options may be appropriate in the advanced disease patient population3
Help appropriate patients who have stopped treatment reestablish tumor control with GLIVEC
Only Approved First-Line Therapy
GLIVEC IS THE ONLY THERAPY APPROVED FOR FIRST-LINE USE IN ADVANCED DISEASE1,2
GLIVEC delivers significant clinical benefit to most patients with KIT+ GIST 3
- Absence of progression is an excellent predictive marker of progression-free survival (PFS) and overall survival (OS) in advanced GIST4
- Patients showing nonprogression of disease by 6 months of treatment had the same outcomes as those who showed complete or partial response4
| Patients With KIT+ GIST Achieving Disease Control with glivec over a 5-year follow-up (n=147)3 |
|---|
 Patients With KIT+ GIST Achieving Disease Control
|
Answer our survey question and receive immediate feedback!
See how Your colleagues around the world respond.